Structure Therapeutics (GPCR) Amortizatization of Intangibles (2022 - 2026)
Structure Therapeutics (GPCR) recorded quarterly Amortizatization of Intangibles of $10000.0 in Q1 2026, down 96.89% quarter-over-quarter from $322000.0 in Q4 2025, and down 99.81% on a YoY basis from $5.2 million in Q1 2025.
Structure Therapeutics (GPCR) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Structure Therapeutics' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $10000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 99.81% year-over-year to $10000.0; the TTM figure through Mar 2026 stood at -$4.8 million (down 351.66% YoY), while the FY2025 annual figure was $345000.0, up 8525.0% from the prior year.
- Amortizatization of Intangibles was $10000.0 for Q1 2026 at Structure Therapeutics, down from $322000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $5.2 million in Q1 2025 to a low of -$9.5 million in Q3 2025.
- Historically, Amortizatization of Intangibles has averaged $75588.2 across 5 years, with a median of $322000.0 in 2025.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles sank 859.41% in 2023, then soared 4700.0% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at $478000.0 in 2022, then tumbled by 859.41% to -$3.6 million in 2023, then surged by 99.81% to -$7000.0 in 2024, then jumped by 4700.0% to $322000.0 in 2025, then tumbled by 96.89% to $10000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $10000.0 (Q1 2026), $322000.0 (Q4 2025), and -$9.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Structure Therapeutics | 9.35 Bn | 9.35 Bn | - | 10,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | 322,000.00 |
| Dec 31, 2025 | 322,000.00 |
| Sep 30, 2025 | -9.51 Mn |
| Sep 30, 2025 | -9.51 Mn |
| Jun 30, 2025 | 4.34 Mn |
| Jun 30, 2025 | 4.34 Mn |
| Mar 31, 2025 | 5.20 Mn |
| Mar 31, 2025 | 5.20 Mn |
| Dec 31, 2024 | -7,000.00 |
| Dec 31, 2024 | -7,000.00 |
| Sep 30, 2024 | -6.45 Mn |
| Sep 30, 2024 | -6.45 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Mar 31, 2024 | 3.28 Mn |
| Mar 31, 2024 | 3.28 Mn |
| Dec 31, 2023 | -3.63 Mn |
| Dec 31, 2023 | -3.63 Mn |